Share Twitter LinkedIn Facebook Email Henry Gómez of Oncosalud – AUNA discusses real-world evidence shows for the first time the practice-changing impact of TAILORx results. Read here: https://www.exactsciences.com/newsroom/new-oncotype-dx-data-asco2020
FDA Approves Deciphera Vimseltinib / Romvimza for symptomatic tenosynovial giant cell tumor (TGCT) patients Other 2 Mins Read
FDA Approves Mirdametinib: Is this the Breakthrough NF1-PN Patients Have Been Waiting For? Other 3 Mins Read
Understanding and Managing BPDCN: Insights from Priyanka Meta’s Conference Presentation Other 2 Mins Read
